# Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Source: https://onco.cc/trials/nct06456138/  
OnCo record `nct06456138` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of trametinib, anlotinib and tislelizumab in lung cancer, run by Shanghai Chest Hospital, not yet recruiting.

## Summary

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC is a phase 1/2, interventional study registered as NCT06456138 by Shanghai Chest Hospital, with a registry enrolment figure of 60 participants, started 2024-07-01 and due to reach its primary completion in 2026-06-30. Interventions recorded: Trametinib; Anlotinib; Tislelizumab. Conditions listed: KRAS Mutation-Related Tumors; Advanced Lung Cancer; Refractory Tumor. Primary outcome: RP2D; PFS. Lung eligibility wording from the registry: "According to the 8th edition of the AJCC/UICC TNM staging system for NSCLC, patients with locally advanced (stage III B/III C), metastatic or recurrent (stage IV) NSCLC confirmed by histology or cytology who are unable to undergo surgery and radical concomitant radiochemotherapy and are confirmed to". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06456138
- Phase: 1/2
- Setting: Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant Advanced Non-small Cell Lung Cancer Patients: a Multi-center, Open-label, Phase 1/2 Study
- Sponsor: Shanghai Chest Hospital
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT06456138: https://clinicaltrials.gov/study/NCT06456138

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/), [Trametinib](https://onco.cc/drugs/trametinib/)
- companies: [BeOne Medicines (formerly BeiGene)](https://onco.cc/companies/beone/), [Novartis](https://onco.cc/companies/novartis/), [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06456138.json